恒瑞医药：子公司获批HRS-7535片Ⅲ期临床试验开展资格

Group 1 - Approval Status: Subsidiary Shandong Shengdi Pharmaceutical received the "Drug Clinical Trial Approval Notice" for HRS-7535, approved to conduct Phase III clinical trials for the treatment of chronic kidney disease [1][2] - Drug Characteristics: A novel oral small molecule GLP-1R agonist, with no similar oral drugs available globally. Mechanism of action includes promoting insulin secretion, lowering glucagon levels, inhibiting gastric emptying, and enhancing satiety. Preclinical data shows significant improvement in chronic kidney disease symptoms in animals [1][2] - R&D Investment: Cumulative R&D investment to date is approximately 369 million yuan (unaudited) [1][2]